Uremic Stomatitis

Uremic stomatitis is a severe, ulcerative, and necrotizing inflammation of the oral mucosa that occurs as a complication of advanced chronic kidney disease (CKD) or acute kidney injury (AKI) with uremia. It is characterized by the accumulation of uremic toxins (e.g., urea, creatinine, phenols, indoles, and advanced glycation end-products) in the blood and tissues, leading to direct mucosal damage, secondary bacterial infection, and impaired tissue repair. The condition is part of the uremic syndrome, which affects multiple organ systems, including the gastrointestinal tract, cardiovascular system, and immune system. In veterinary medicine, uremic stomatitis is most commonly recognized in dogs and cats with chronic kidney disease (IRIS stages 3 and 4) or acute uremic crises. The oral lesions are often painful, leading to anorexia, weight loss, and a significant decline in quality of life. The condition is a marker of severe renal dysfunction and carries a guarded to poor prognosis unless the underlying renal disease is managed aggressively. Uremic stomatitis is distinct from other oral ulcerative conditions (e.g., chronic ulcerative paradental stomatitis, eosinophilic granuloma complex) by its association with azotemia and systemic signs of uremia.

The primary etiology of uremic stomatitis is the retention of uremic toxins due to impaired renal excretion. In chronic kidney disease, progressive nephron loss leads to decreased glomerular filtration rate (GFR) and accumulation of nitrogenous waste products (urea, creatinine), as well as other toxins such as phenols, indoles, and middle molecules (e.g., beta-2-microglobulin). In acute kidney injury, sudden loss of renal function results in rapid accumulation of these toxins. Specific etiologic factors include: 1) Chronic kidney disease (CKD) – the most common cause, often due to chronic interstitial nephritis, glomerulonephritis, amyloidosis, or polycystic kidney disease; 2) Acute kidney injury (AKI) – caused by toxins (e.g., ethylene glycol, lilies in cats), ischemia, sepsis, or urinary obstruction; 3) Uremic toxins – urea itself is not directly toxic, but its breakdown to ammonia in the oral cavity (via urease-producing bacteria) contributes to mucosal irritation; other toxins like indoxyl sulfate and p-cresol have direct cytotoxic effects; 4) Secondary bacterial infection – the compromised mucosal barrier allows overgrowth of oral flora (e.g., Pasteurella, Streptococcus, Staphylococcus, and anaerobic species), exacerbating inflammation and necrosis; 5) Hyperphosphatemia and secondary hyperparathyroidism – elevated phosphate and parathyroid hormone (PTH) contribute to soft tissue calcification and impaired wound healing; 6) Metabolic acidosis – systemic acidosis alters cellular function and impairs tissue repair; 7) Malnutrition and cachexia – uremia causes anorexia and altered protein metabolism, leading to poor tissue resilience; 8) Immunosuppression – uremia impairs neutrophil and lymphocyte function, increasing susceptibility to infection. The exact molecular triggers include oxidative stress, activation of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6), and apoptosis of epithelial cells.

Uremic stomatitis is a complication of renal failure and therefore its epidemiology mirrors that of CKD and AKI in dogs and cats. In dogs, CKD is common in older animals (median age 9-10 years), with certain breeds predisposed, including the Cavalier King Charles Spaniel (glomerulonephritis), Bull Terrier (hereditary nephritis), and Samoyed (X-linked hereditary nephritis). In cats, CKD is highly prevalent, affecting approximately 30-40% of cats over 10 years of age, with a median age of 12-15 years. There is no strong sex predilection, but some studies suggest a slight male predominance in cats. Uremic stomatitis is more likely to occur in advanced stages of CKD (IRIS stage 3 or 4) or during acute uremic crises. The exact incidence of uremic stomatitis is not well documented, but it is estimated to occur in a significant proportion of animals with severe azotemia (BUN > 100 mg/dL, creatinine > 5 mg/dL). Geographic variation is not significant, but environmental factors such as access to nephrotoxic substances (e.g., ethylene glycol, lilies) can influence the incidence of AKI and subsequent uremic stomatitis. In cats, chronic gingivostomatitis is a separate entity, but uremic stomatitis is specifically linked to renal failure and is not breed-specific. The condition is more common in animals with concurrent conditions such as diabetes mellitus, hypertension, and urinary tract infections, which can accelerate renal decline.

The pathophysiology of uremic stomatitis is multifactorial, involving direct toxic effects of uremic toxins, secondary bacterial invasion, and impaired host defenses. Uremic toxins, including urea, creatinine, phenols, indoles, and advanced glycation end-products, accumulate in the blood and diffuse into the oral mucosa. Urea is hydrolyzed by bacterial urease in the oral cavity to form ammonia, which is directly caustic to the mucosal epithelium, causing chemical burns and ulceration. Other toxins, such as indoxyl sulfate and p-cresol, are protein-bound and exert cytotoxic effects by inducing oxidative stress, mitochondrial dysfunction, and apoptosis in epithelial cells. These toxins also activate inflammatory pathways, leading to upregulation of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6) and adhesion molecules, promoting leukocyte infiltration and tissue damage. Hyperphosphatemia and secondary hyperparathyroidism contribute to soft tissue calcification, which can impair blood flow and tissue repair. Metabolic acidosis, common in uremia, disrupts intracellular pH homeostasis and enzyme function, further compromising mucosal integrity. The oral mucosa becomes erythematous, edematous, and friable, with the formation of ulcers, pseudomembranes, and necrotic debris. Secondary bacterial infection, particularly with anaerobic and Gram-negative organisms, exacerbates the inflammation and leads to tissue necrosis. The uremic state also causes immunosuppression, with impaired neutrophil chemotaxis, phagocytosis, and lymphocyte function, allowing bacterial overgrowth and delayed healing. Additionally, uremia is associated with malnutrition and cachexia, leading to reduced protein synthesis and impaired epithelial regeneration. The combination of these factors results in the characteristic lesions of uremic stomatitis: multifocal to diffuse ulceration, necrosis, and halitosis. Systemic complications, such as gastrointestinal ulceration, pancreatitis, and cardiovascular disease, can further worsen the clinical picture.

Predisposing factors for uremic stomatitis include: 1) Chronic kidney disease (CKD) – any underlying cause of CKD, such as chronic interstitial nephritis, glomerulonephritis, amyloidosis, or polycystic kidney disease, predisposes to uremia; 2) Acute kidney injury (AKI) – exposure to nephrotoxins (ethylene glycol, lilies, NSAIDs, aminoglycosides), ischemia, sepsis, or urinary obstruction can precipitate acute uremia; 3) Age – older animals are more prone to CKD and thus to uremic stomatitis; 4) Breed – certain breeds have hereditary nephropathies (e.g., Bull Terrier, Samoyed, Cavalier King Charles Spaniel) that increase risk; 5) Concurrent diseases – diabetes mellitus, hypertension, hyperthyroidism (in cats), and urinary tract infections can accelerate renal decline; 6) Dietary factors – high protein diets may increase urea production, but the role of diet in uremic stomatitis is not fully established; 7) Poor oral hygiene – pre-existing dental disease and periodontitis can provide a portal of entry for bacteria and exacerbate mucosal damage; 8) Immunosuppression – concurrent immunosuppressive therapy or diseases (e.g., FIV, FeLV in cats) can increase susceptibility to secondary infections; 9) Medications – drugs that reduce renal perfusion (e.g., NSAIDs, diuretics) or are nephrotoxic can worsen renal function; 10) Dehydration – inadequate water intake can worsen azotemia and toxin concentration.

Clinical signs of uremic stomatitis are often part of the broader uremic syndrome and include: 1) Oral signs – halitosis (uremic breath, often described as 'urine-like' or 'ammoniacal'), oral pain, excessive drooling (ptyalism), reluctance to eat (anorexia), and visible oral lesions. On examination, the oral mucosa may be erythematous, edematous, and ulcerated. Ulcers are often covered with a grayish-white pseudomembrane or necrotic debris. The gingiva, buccal mucosa, tongue, and hard palate may be affected. In severe cases, there may be oronasal fistulas or bleeding from the oral cavity. 2) Systemic signs – depression, lethargy, weakness, weight loss, and poor body condition. 3) Gastrointestinal signs – vomiting, diarrhea, and nausea, which are common due to uremic gastroenteritis. 4) Renal signs – polyuria, polydipsia, dehydration, and in advanced cases, oliguria or anuria. 5) Cardiovascular signs – hypertension, which may be detected on ophthalmic examination (retinal hemorrhages, detachment) or by Doppler blood pressure measurement. 6) Neurologic signs – in severe uremia, encephalopathy can cause seizures, tremors, or coma. 7) Hematologic signs – non-regenerative anemia due to decreased erythropoietin production and uremic toxin-induced red blood cell damage. 8) Endocrine signs – secondary hyperparathyroidism may cause bone resorption and soft tissue calcification. The severity of clinical signs correlates with the degree of azotemia and the chronicity of renal failure. In peracute cases (e.g., ethylene glycol toxicity), oral lesions may develop rapidly within 24-48 hours. In chronic cases, the onset is insidious, and owners may notice gradual weight loss, poor appetite, and worsening halitosis.

Differential diagnoses for uremic stomatitis include: 1) Chronic ulcerative paradental stomatitis (CUPS) – a common inflammatory condition in dogs, especially in breeds like the Maltese and Cavalier King Charles Spaniel. It is characterized by painful ulcers along the buccal mucosa adjacent to teeth. Unlike uremic stomatitis, CUPS is not associated with azotemia, and lesions often improve with dental cleaning and immunosuppressive therapy. 2) Eosinophilic granuloma complex (EGC) – seen in cats, presents as raised, ulcerated plaques or linear granulomas on the lips, tongue, or palate. EGC is often associated with allergies or immune-mediated disease, and histopathology reveals eosinophilic infiltrates. No azotemia is present. 3) Oronasal fistula – a communication between the oral and nasal cavities, often due to dental disease or trauma. It presents with nasal discharge and sneezing, but no systemic signs of uremia. 4) Oral neoplasia – squamous cell carcinoma, melanoma, or fibrosarcoma can cause oral ulcers and masses. Biopsy is definitive, and azotemia is absent. 5) Immune-mediated diseases – such as pemphigus vulgaris or bullous pemphigoid, which cause vesiculobullous lesions that rupture to form ulcers. These are often responsive to immunosuppressive therapy and are not associated with renal failure. 6) Calicivirus infection in cats – causes oral ulcers and upper respiratory signs, but no azotemia. 7) Toxic insults – ingestion of caustic substances (e.g., household cleaners) can cause oral ulceration, but history and lack of azotemia differentiate. 8) Severe periodontitis – can cause gingival ulceration and halitosis, but systemic signs are absent. 9) Uremic gastritis – may cause vomiting, but oral lesions are not present. 10) Heavy metal toxicity – e.g., thallium or mercury can cause oral ulceration, but these are rare and not associated with azotemia. Definitive diagnosis of uremic stomatitis requires documentation of azotemia (elevated BUN and creatinine) and exclusion of other causes of oral ulceration.

The diagnostic algorithm for uremic stomatitis begins with a thorough history and physical examination, with emphasis on the oral cavity and systemic signs. 1) Initial assessment: Obtain a complete blood count (CBC), serum biochemistry profile, and urinalysis. The presence of azotemia (BUN > 30 mg/dL, creatinine > 1.6 mg/dL in dogs, > 2.0 mg/dL in cats) and urine specific gravity (USG) < 1.030 in dogs or < 1.035 in cats suggests renal azotemia. 2) Confirm renal disease: If azotemia is present, assess urine sediment, urine protein-to-creatinine ratio (UPC), and blood pressure. Renal imaging (abdominal ultrasound) may be performed to evaluate kidney size, echogenicity, and structure. 3) Stage the disease: Use the IRIS (International Renal Interest Society) staging system for CKD based on fasting creatinine levels and proteinuria. Uremic stomatitis is more common in stages 3 and 4. 4) Oral examination: Perform a thorough oral examination under sedation or anesthesia, if necessary, to document the extent of lesions. Biopsy of oral lesions may be indicated to rule out other causes, but histopathology typically shows nonspecific ulcerative and necrotizing inflammation. 5) Additional tests: Measure blood pressure (Doppler or oscillometric) to detect hypertension. Assess acid-base status via blood gas analysis. Evaluate for concurrent conditions such as pancreatitis (fPLI or cPLI), urinary tract infection (urine culture), and hyperthyroidism in cats. 6) Exclude other causes of oral ulceration: If azotemia is not present, consider other differentials. If azotemia is present, the diagnosis of uremic stomatitis is likely, but rule out other causes of oral lesions that may coexist. 7) Advanced imaging: In cases of suspected oronasal fistula or neoplasia, dental radiographs or CT may be indicated. 8) Response to therapy: A positive response to treatment of uremia (e.g., fluid therapy, phosphate binders) with improvement in oral lesions supports the diagnosis.

Laboratory findings in uremic stomatitis reflect the underlying renal failure and the systemic effects of uremia. 1) Hematology: Non-regenerative anemia is common due to decreased erythropoietin production and shortened red blood cell lifespan. Hematocrit may be low (e.g., < 30% in dogs, < 25% in cats). Red blood cell morphology may show anisocytosis, poikilocytosis, and schistocytes. Leukocytosis may be present due to stress or secondary infection. Platelet function may be impaired, leading to bleeding tendencies. 2) Serum biochemistry: Marked azotemia (BUN > 60 mg/dL, creatinine > 3.0 mg/dL) is typical. Hyperphosphatemia (phosphate > 6.0 mg/dL) is common. Hyperkalemia may occur in oliguric or anuric patients. Metabolic acidosis is indicated by decreased bicarbonate (HCO3- < 18 mEq/L) and low pH on blood gas analysis. Hypercalcemia or hypocalcemia may be present; hypercalcemia can contribute to renal calcification, while hypocalcemia may be due to hyperphosphatemia. Elevated liver enzymes (ALT, AST) may be seen due to uremic gastroenteritis or concurrent disease. Total protein may be low due to proteinuria or malnutrition. 3) Urinalysis: Urine specific gravity is often isosthenuric (1.008-1.012) in CKD, but may be low in AKI. Proteinuria is common, and UPC ratio > 0.5 in dogs and > 0.4 in cats indicates significant proteinuria. Urine sediment may show casts, red blood cells, white blood cells, and bacteria if infection is present. 4) Blood gas analysis: Metabolic acidosis with low pH, low bicarbonate, and low base excess. 5) Specific biomarkers: SDMA (symmetric dimethylarginine) is an early marker of renal dysfunction and may be elevated even when creatinine is normal. In cats, fPLI (feline pancreatic lipase immunoreactivity) may be elevated if pancreatitis is concurrent. NT-proBNP may be elevated in cats with cardiac disease, which can be a comorbidity. C-reactive protein (CRP) may be elevated as an inflammatory marker. 6) Serology/PCR: Tests for infectious diseases (e.g., FeLV, FIV in cats, leptospirosis in dogs) may be indicated. 7) Endocrine assays: Thyroid hormone levels (T4) in cats to rule out hyperthyroidism, which can cause renal dysfunction.

Imaging findings in uremic stomatitis are primarily related to the renal disease and may include: 1) Abdominal radiography: May show small, irregular kidneys in CKD, or enlarged kidneys in AKI (e.g., due to ethylene glycol toxicity). Radiopaque calculi may be visible in cases of urolithiasis. 2) Abdominal ultrasonography: In CKD, kidneys are often small, with increased echogenicity, loss of corticomedullary distinction, and irregular contours. In AKI, kidneys may be enlarged and hyperechoic. Ultrasonography can also detect renal cysts, tumors, or hydronephrosis. Doppler ultrasound can assess renal blood flow. 3) Thoracic radiography: May be indicated to evaluate for pulmonary edema or metastatic calcification in advanced uremia. 4) Dental radiography: In cases of concurrent dental disease, dental radiographs can assess tooth root abscesses or bone loss. 5) Computed tomography (CT): May be used for detailed evaluation of the oral cavity, especially if neoplasia or oronasal fistula is suspected. CT can also assess renal size and structure. 6) Magnetic resonance imaging (MRI): Rarely needed, but may be used for brain imaging if uremic encephalopathy is suspected. 7) Endoscopy: Upper gastrointestinal endoscopy may reveal uremic gastritis or ulcers, but is not routinely performed for oral lesions. 8) Echocardiography: May be indicated if cardiac disease is suspected, as hypertension and uremic cardiomyopathy can occur.

Cytology and histopathology of oral lesions in uremic stomatitis are nonspecific but can help rule out other causes. 1) Fine needle aspirate (FNA) of oral masses or ulcers: Cytology may show mixed inflammatory cells (neutrophils, macrophages, lymphocytes) and necrotic debris. No neoplastic cells are seen. 2) Oral mucosal biopsy: Histopathology typically reveals ulceration of the squamous epithelium with necrosis, fibrinopurulent exudate, and granulation tissue. There is often a mixed inflammatory infiltrate with neutrophils, macrophages, and lymphocytes. In chronic cases, fibrosis and epithelial hyperplasia may be present. Special stains (e.g., Gram stain) may reveal bacteria. No specific viral inclusions or fungal organisms are seen. 3) Renal biopsy: If the underlying renal disease is uncertain, a renal biopsy may be performed, but it is not necessary for the diagnosis of uremic stomatitis. Renal histopathology can identify the underlying cause (e.g., glomerulonephritis, interstitial nephritis, amyloidosis). 4) Immunohistochemistry: May be used to detect immune complex deposition in renal biopsies, but is not routinely performed for oral lesions.

Treatment of uremic stomatitis is primarily directed at managing the underlying renal failure and providing supportive care for the oral lesions. 1) Emergency stabilization: If the animal is dehydrated or in shock, intravenous fluid therapy with isotonic crystalloids (e.g., Lactated Ringer's solution or 0.9% NaCl) is initiated. The rate is calculated based on dehydration deficit (e.g., 5-10% of body weight) plus maintenance (e.g., 40-60 ml/kg/day in dogs, 50-70 ml/kg/day in cats) plus ongoing losses. In oliguric or anuric patients, fluid therapy must be carefully monitored to avoid fluid overload. 2) Correction of electrolyte and acid-base imbalances: Hyperkalemia may be treated with insulin (0.1 U/kg IV) and dextrose (2 g/U insulin), or with calcium gluconate (0.5-1 ml/kg IV over 10-20 minutes) for cardioprotection. Metabolic acidosis is corrected with sodium bicarbonate (0.5-1 mEq/kg IV slowly) if pH < 7.2 or bicarbonate < 12 mEq/L. 3) Management of uremia: Phosphate binders (e.g., aluminum hydroxide 30-100 mg/kg/day PO divided with meals) are used to control hyperphosphatemia. A renal diet low in protein, phosphorus, and sodium is recommended. In severe cases, dialysis (hemodialysis or peritoneal dialysis) may be considered, but is not widely available. 4) Oral care: The oral cavity should be gently cleaned with chlorhexidine solution (0.12%) or diluted povidone-iodine. Analgesics are essential; opioids (e.g., buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h) or NSAIDs (e.g., meloxicam 0.1 mg/kg PO q24h in dogs, but caution in renal disease) may be used, but NSAIDs are generally avoided in renal failure. 5) Antibiotics: If secondary bacterial infection is suspected, broad-spectrum antibiotics such as amoxicillin-clavulanate (12.5-25 mg/kg PO q12h) or clindamycin (5-10 mg/kg PO q12h) may be indicated. However, antibiotics should be used judiciously and based on culture if possible. 6) Nutritional support: Anorexia is common; placement of a feeding tube (nasoesophageal, esophagostomy, or gastrostomy) may be necessary to provide adequate nutrition. 7) Management of hypertension: If systolic blood pressure > 160 mmHg, amlodipine (0.1-0.25 mg/kg PO q24h in dogs, 0.625-1.25 mg/cat PO q24h) may be used. 8) Treatment of anemia: Erythropoietin (100 U/kg SC three times weekly) may be considered, but is expensive and may cause pure red cell aplasia. 9) Gastrointestinal protectants: Sucralfate (0.5-1 g PO q8h) or omeprazole (0.5-1 mg/kg PO q12h) may be used to prevent uremic gastritis. 10) Surgical intervention: In rare cases, if there is severe necrosis or oronasal fistula, surgical debridement may be considered, but is often not recommended due to poor healing. 11) Alternative therapies: Some studies suggest that omega-3 fatty acids may have renoprotective effects, but evidence is limited.

The prognosis for uremic stomatitis is guarded to poor, as it indicates severe renal dysfunction. The underlying renal disease is often progressive and irreversible. Short-term prognosis depends on the response to fluid therapy and management of uremia. If azotemia improves with treatment, oral lesions may partially heal, but they often recur. Long-term prognosis is poor, with median survival times for dogs with IRIS stage 4 CKD of approximately 1-2 months, and for cats with stage 4 CKD of approximately 1-3 months. Negative prognostic indicators include: severe azotemia (creatinine > 5 mg/dL), oliguria or anuria, hyperkalemia, metabolic acidosis, proteinuria (UPC > 2.0), hypertension, and concurrent diseases (e.g., pancreatitis, diabetes). The presence of uremic stomatitis itself is a marker of advanced disease and is associated with a poor quality of life. Euthanasia is often considered when the animal is refractory to treatment and has a poor quality of life. However, with aggressive management, some animals may have a reasonable quality of life for weeks to months.

Follow-up for uremic stomatitis involves regular monitoring of renal function and oral lesions. 1) Re-check examinations: Initially, re-check every 1-2 weeks until the animal is stable, then every 1-3 months. 2) Laboratory monitoring: Serial serum biochemistry (BUN, creatinine, phosphorus, potassium, bicarbonate) and urinalysis (USG, UPC) should be performed at each re-check. SDMA may be used to monitor renal function. 3) Blood pressure monitoring: Check blood pressure at each re-check, and adjust antihypertensive therapy as needed. 4) Oral examination: Inspect the oral cavity at each visit to assess healing and detect new lesions. 5) Imaging: Abdominal ultrasound may be repeated every 3-6 months to monitor kidney size and structure. 6) Dietary management: Ensure the animal is eating a renal diet; adjust caloric intake as needed. 7) Medication adjustments: Phosphate binders and other medications should be adjusted based on laboratory results. 8) Owner education: Discuss the progressive nature of the disease, signs of uremia, and when to consider euthanasia. 9) Quality of life assessment: Use a quality-of-life scale to help owners make decisions.

Pearls: 1) Uremic stomatitis is a marker of severe renal failure; always evaluate renal function in any animal with oral ulceration and halitosis. 2) The oral lesions are often painful; provide adequate analgesia to improve appetite and quality of life. 3) Fluid therapy is the cornerstone of treatment; correct dehydration and maintain perfusion to improve renal function. 4) Phosphate binders are essential to control hyperphosphatemia and slow progression of CKD. 5) A renal diet is crucial; avoid high-protein diets that increase urea production. 6) Monitor blood pressure and treat hypertension to prevent further renal damage. 7) Use antibiotics only if there is evidence of secondary infection; avoid nephrotoxic drugs. 8) Consider feeding tube placement early to ensure adequate nutrition. Pitfalls: 1) Do not use NSAIDs in animals with renal failure; they can worsen renal function. 2) Avoid overhydration, especially in oliguric animals; monitor urine output and body weight. 3) Do not ignore hyperkalemia; it can cause cardiac arrhythmias and death. 4) Do not delay treatment of metabolic acidosis; severe acidosis can be fatal. 5) Do not assume that oral lesions are solely due to uremia; always rule out other causes, especially neoplasia. 6) Do not forget to check for concurrent diseases such as pancreatitis, diabetes, and hyperthyroidism. 7) Do not give aluminum hydroxide in large doses without monitoring for constipation or aluminum toxicity. 8) Do not use erythropoietin without monitoring for red cell aplasia.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for uremic stomatitis and its underlying renal failure: 1) Fluid therapy: Lactated Ringer's solution or 0.9% NaCl IV; shock dose: 60-90 ml/kg in dogs, 40-60 ml/kg in cats, given over 15-30 minutes; maintenance: 40-60 ml/kg/day in dogs, 50-70 ml/kg/day in cats; adjust based on hydration status and urine output. 2) Phosphate binders: Aluminum hydroxide (e.g., Amphojel) 30-100 mg/kg/day PO divided with meals; start at 30 mg/kg/day and titrate to maintain serum phosphorus < 5.5 mg/dL. 3) Antacids: Sucralfate 0.5-1 g PO q8h in dogs, 0.25-0.5 g PO q8h in cats; administer 30 minutes before meals. 4) H2 blockers or proton pump inhibitors: Famotidine 0.5-1 mg/kg PO/IV q12h; Omeprazole 0.5-1 mg/kg PO q12h. 5) Antiemetics: Maropitant (Cerenia) 1 mg/kg SC q24h or 2 mg/kg PO q24h; Ondansetron 0.1-0.2 mg/kg IV q8h. 6) Analgesics: Buprenorphine 0.01-0.02 mg/kg IV/IM/SC q8-12h; for severe pain, fentanyl CRI at 2-5 mcg/kg/hr. 7) Antibiotics: Amoxicillin-clavulanate 12.5-25 mg/kg PO q12h; Clindamycin 5-10 mg/kg PO q12h; Metronidazole 10-15 mg/kg PO q12h (for anaerobic coverage). 8) Antihypertensives: Amlodipine 0.1-0.25 mg/kg PO q24h in dogs; 0.625-1.25 mg/cat PO q24h; start at low dose and titrate. 9) Erythropoietin: Recombinant human erythropoietin 100 U/kg SC three times weekly; monitor PCV and blood pressure. 10) Potassium supplementation: If hypokalemia is present, potassium chloride or gluconate 0.1-0.5 mEq/kg/hr IV, or oral potassium gluconate 2-4 mEq/cat/day. 11) Sodium bicarbonate: 0.5-1 mEq/kg IV slowly over 15-30 minutes, or 8-12 mg/kg PO q8-12h for chronic acidosis. 12) Insulin and dextrose for hyperkalemia: Regular insulin 0.1 U/kg IV, followed by dextrose 2 g per unit of insulin IV. 13) Calcium gluconate 10%: 0.5-1 ml/kg IV over 10-20 minutes for cardiac protection in hyperkalemia. 14) Nutritional support: Renal diet (e.g., Hill's k/d, Royal Canin Renal) – feed 60-70% of resting energy requirement initially, gradually increase. 15) Omega-3 fatty acids: Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at 40-100 mg/kg/day PO. All dosages should be adjusted based on renal function, and caution is advised with drugs that are renally excreted.

Evidence-based literature on uremic stomatitis is limited, but the condition is well-recognized as a complication of uremia. Key studies and consensus guidelines include: 1) IRIS (International Renal Interest Society) staging guidelines for CKD, which recommend monitoring for uremic complications such as stomatitis. 2) Studies on uremic toxins (e.g., indoxyl sulfate, p-cresol) have demonstrated their cytotoxic effects on epithelial cells, supporting the pathogenesis of uremic stomatitis. 3) Clinical trials on phosphate binders (e.g., aluminum hydroxide, sevelamer) have shown efficacy in controlling hyperphosphatemia and slowing CKD progression, which may reduce the severity of uremic complications. 4) Research on renal diets has shown that protein restriction reduces urea generation and may alleviate uremic signs, including oral lesions. 5) A study by Polzin et al. (2005) on CKD in dogs reported that survival time is inversely correlated with serum creatinine and proteinuria, and that aggressive management of uremia improves quality of life. 6) In cats, a study by Boyd et al. (2008) found that survival in CKD is influenced by IRIS stage, proteinuria, and hypertension. 7) The use of amlodipine for hypertension in cats with CKD has been shown to reduce systemic blood pressure and slow progression of renal disease (Jepson et al., 2007). 8) A consensus statement from ACVIM on the treatment of CKD in dogs and cats (2019) recommends a multimodal approach including fluid therapy, phosphate binders, renal diet, and management of complications such as anemia and hypertension. 9) There are no specific randomized controlled trials on the treatment of uremic stomatitis itself, but anecdotal evidence and clinical experience suggest that controlling uremia and providing supportive oral care improves the condition. 10) Future research should focus on the role of specific uremic toxins in oral mucosal damage and the efficacy of targeted therapies such as AST-120 (an oral adsorbent) in reducing toxin levels.